Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
All news
Biotechnology
Beijing’s Sinovac Biotech has secured approximately $500 million in funding for further development, capacity expansion and manufacturing of its coronavirus vaccine. 8 December 2020
Biotechnology
Dutch gene therapy company uniQure today announced the late-breaking presentation of initial data from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe and moderately severe hemophilia B. 8 December 2020
Biotechnology
US cell therapy company Bellicum Pharmaceuticals closed 10% lower on Monday. 8 December 2020
Biotechnology
China’s National Medical Products Administration (NMPA) has approved Takhzyro (lanadelumab) subcutaneous injection for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older. 8 December 2020
Biotechnology
US biopharma TG Therapeutics has announced two data sets at the 62nd American Society of Hematology (ASH) Annual Meeting. 7 December 2020
Biotechnology
USA-based KaliVir Immunotherapeutics today announced a worldwide licensing agreement with Japan’s Astellas Pharma for the research, development and commercialization of VET2-L2, an intravenously administered oncolytic virus for immuno-oncology, as well as a research collaboration to generate a second product, a follow-on virus. 7 December 2020
Biotechnology
Gilead Sciences company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study evaluating Yescarta (axicabtagene ciloleucel) in adults with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) after at least two prior lines of therapy. 7 December 2020
Biotechnology
Translarna (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD). 7 December 2020
Biotechnology
Shares in Tonix Pharmaceuticals were up by more than a third after 90 minutes of trading on Monday. 7 December 2020
Biotechnology
Swiss pharma major Roche has presented a new analysis of three-year follow-up data from the pivotal HAVEN 1-4 studies. 7 December 2020
Biotechnology
US biotech Syros Pharmaceuticals has acquired SY-2101, a clinical-stage drug candidate formerly known as ORH-2014, from Orsenix. 7 December 2020
Biotechnology
Germany’s Bayer and US biotech Atara Biotherapeutics today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR-T cell therapies for the treatment of solid tumors, with news of the deal pushing Atara’s shares up 10.6% to $27.20 pre-market. 7 December 2020
Biotechnology
Japan’s largest rugmaker Takeda Pharmaceutical on Friday announced positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. 7 December 2020
Biotechnology
Kite today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus (brexucabtagene autoleucel, formerly KTE-X19) in adult patients with relapsed or refractory mantle cell lymphoma (MCL), at the 62nd ASH Annual Meeting and Exposition. 7 December 2020
Biotechnology
New data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta/Venclyxto (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). 7 December 2020
Biotechnology
US biotech major Gilead Sciences’ Kite subsidiary today announced strong four-year follow-up data from the pivotal ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL). 5 December 2020
Biotechnology
US biotech Incyte today announced detailed results from the pivotal Phase III REACH3 study that demonstrate Jakafi (ruxolitinib) significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GVHD) compared to best available therapy (BAT). 5 December 2020
Biotechnology
China-based immuno-oncology-focussed biotech I-Mab Biopharma today announced the advancement of clinical development of its highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the USA and China, achieving milestones as planned. 4 December 2020
Biotechnology
The pharmaceutical arm of Johnson & Johnson has submitted to the US regulator for approval to market amivantamab in non-small cell lung cancer (NSCLC). 4 December 2020
Biotechnology
French immunotherapy specialist Transgene said yesterday that its board had approved the appointment of Hedi Ben Brahim as its new chairman and chief executive, effective January 1, 2021. 4 December 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze